In May, the Trump administration published an executive order requiring drug companies to bring prices in line with those paid by other developed nations, otherwise known as Most Favored Nation (MFN) pricing. Although the June 11 deadline has come and gone, no details have been released as to whether drug companies have opted to negotiate or if the government will implement any enforcement action.
Impact of Travel Ban, J-1 Visa Interview Pause on Rheumatology
A temporary suspension of new interviews for J-1 visas and an ongoing travel ban preventing nationals of 12 countries from entering the U.S. are likely to have a range of impacts on graduate medical training, the rheumatology workforce and research collaborations.
Arkansas Leads the Nation with Landmark Pharmacy Benefit Manager Reform
Signed into law in April, the legislation will ban direct and indirect PBM ownership of pharmacies, effective Jan. 1, 2026. It addresses longstanding concerns about conflicts of interest, market consolidation and patient access created by vertically integrated PBM pharmacy models.
Legal Updates: Compliance Planning for Your Practice
Physicians have a lot going on. Between the pressures of clinical and administrative responsibilities, sometimes the only way to keep everything together is with a to-do list. Unfortunately, it can often feel as though some items never come off that list. Often, the bigger a project sounds, the more likely it is to sit on…
A Look Back at 2024 Regulatory Developments
In 2024, key federal healthcare regulations and policy developments—related to health insurance, privacy protections, reimbursement, biosimilar use and more—shaped the landscape of the practice of rheumatology in several important ways.
Federally Funded Providers Must Provide Language Assistance Services by July 5
By July 5, all providers who participate in federally funded healthcare programs, including Medicare and Medicaid, must provide language assistance programs for patients to meet requirements of Section 1557 of the Affordable Care Act.
Telemedicine Flexibilities for Controlled Substance Prescriptions Extended Through 2025
A third extension of telemedicine flexibilities will continue to allow prescription of controlled substances via telemedicine without an in-person visit through the end of 2025.
Status Check: Non-Compete Agreements in Healthcare
The FTC issued a Final Rule that banned non-compete agreements, but the rule was recently halted by a nationwide injunction from a federal court in Texas.
‘Don’t Block Patient Access to Records,’ says HHS to Healthcare Providers
The Department of Health & Human Services has released a final rule that would penalize healthcare providers who interfere with a patient’s access to, exchange or use of their electronic health information.
Unpacking the Court: An Analysis of Recent Supreme Court Decisions
Two recent Supreme Court decisions, Trump v. United States and Loper Bright Enterprises v. Raimond, have broad implications for administrative authority and regulatory advocacy. Joseph Cantrell, JD, analyzes how these decisions may affect the relative power of the different branches of government.
- 1
- 2
- 3
- …
- 19
- Next Page »